Visualitzant O - Articles científics per títol

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

Gorbatenko, Andrej; Søkilde, Rolf; Sorensen, Ester E.; Newie, Inga; Persson, Helena; Morancho Armisen, Beatriz; Arribas López, Joaquin Vicente (Nature Publishing Group, 2019-03-04)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Manca, Paolo; Corso, Simona; Raimondi, Alessandra; Berrino, Enrico; Tabernero Caturla, Josep; Pietrantonio, Filippo; Bellomo, Sara Erika (American Association for Cancer Research, 2023-02-01)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

DIECI, MARIA VITTORIA; Griguolo, Gaia; Marín-Aguilera, Mercedes; GUARNERI, VALENTINA; Brasó Maristany, Fara; Paré, Laia; Vivancos, Ana (Elsevier, 2022-11)

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

Sánchez-Heras, A. Beatriz; Castillejo, Adela; García-Díaz, Juan D.; Teulé, Alexandre; Sánchez, Rosario; Lopez Fernandez, Adrià; Balmaña Gelpí, Judith; Robledo, Mercedes (MDPI, 2020-11-05)

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

yu, helena; Goto, Yasushi; Hayashi, Hidetoshi; FELIP, ENRIQUETA; Yang, James Chih-Hsin; Reck, Martin (American Society of Clinical Oncology, 2023-12-10)

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Yu, Helena A; Hayashi, Hidetoshi; Goto, Yasushi; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Future Medicine, 2023-06)

Hierarchical chromatin organization detected by TADpole

Soler-Vila, Paula; Cusco Pons, Pol; Farabella, Irene; Di Stefano, Marco; Marti-Renom, Marc A. (Oxford University Press , 2020-04-17)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

Miyoshi, Yasuo; Yoshimura, Yuta; Saito, Kenichi; Muramoto, Kenzo; Sugawara, Michiko; Alexis, Karenza; Cortés Castan, Javier (Springer, 2020-07)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

Iranzo Gómez, Patricia; Pardo Aranda, Nuria; Callejo Perez, Ana; Cedres Perez, Susana; Martínez Marti, Alexandre; Navarro Mendivil, Alejandro; Soleda, Mireia; Jiménez Flores, José Antonio; Hernandez Losa, Javier; Vivancos Prellezo, Ana; Felip Font, Enriqueta; Amat, Ramon; Carbonell, Caterina; Frigola Rissech, Joan (BMJ, 2022-04)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07)

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Koessler, Thibaud; Alsina Maqueda, Maria; Arnold, Dirk; Ben-Aharon, Irit; Lutz, Manfred; Obermannova, Radka (Springer Nature, 2021-09)

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

Villanueva Cardús, Josep; Bellio, Chiara (AME Publishing Company, 2020-07)

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Pujals-Pruneda, Mireia; Resar, Linda; Villanueva Cardús, Josep (MDPI, 2021-09-09)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Yndestad, Synnøve; Engebrethsen, Christina; Nikolaienko, Oleksii; Vintermyr, Olav Karsten ; Lillestøl, Reidun; Llop-Guevara, Alba; Herencia Ropero, Andrea; Serra, Violeta (American Society of Clinical Oncology, 2023-12-01)

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Pellegrino, B.; Musolino, Antonio; Llop Guevara, Alba; Serra Elizalde, Violeta; De Silva, P.; Hlavata, Z. (Elsevier, 2020-02-01)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Serra Camprubi, Queralt; Verdaguer Mata, Helena; Oliveros, Winona; Lupión-Garcia, Núria; Llop Guevara, Alba; Molina, Cristina; Vila Casadesus, Maria; Querol Paños, Jessica; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Serra Elizalde, Violeta; Arribas López, Joaquin Vicente; Tabernero Caturla, Josep; Peiro Sales, Sandra; Macarulla Mercadé, Teresa; Tian, Tian V; Bernadó Morales, Cristina; Arenas Lahuerta, Enrique Javier; Frigola Rissech, Joan; Fabregat Franco, Carles; Castet, Florian; Miquel Aymar, Josep Maria; Escudero Iriarte, Carmen; Yáñez, Mariana; Escorihuela Baez, Marta (American Association for Cancer Research, 2023-01-17)

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Alpuim Costa, Diogo; Nobre, José Guilherme; Vaz Batista, Marta; Ribeiro, Catarina; Calle, Catarina; Cortés, A.; Cortés Castan, Javier (Frontiers Media, 2021-02)

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ramos, Javier; Vega, Juan Francisco; Cruz, Victor; Sanchez-Sanchez, Eduardo; Cortés Castan, Javier; Martinez-Salazar, Javier (MDPI, 2019-03-01)

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Tempero, Margaret A.; Tabernero Caturla, Josep; Reni, Michele; Van Cutsem, Eric; Hendifar, Andrew E.; Macarulla Mercadé, Teresa; Oh, Do-Youn (Elsevier, 2021-05)

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Giné Soca, Eva; de la Cruz, Fatima; Jimenez-Ubieto, Ana; Terol, M. Jose; Marin Niebla, Ana; Martín García-Sancho, Alejandro; Lopez-Jimenez, Javier (American Society of Clinical Oncology, 2022-04-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Hierarchical chromatin organization detected by TADpole

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 ﻿

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial ﻿

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial ﻿

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization ﻿

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy ﻿

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC ﻿

Hierarchical chromatin organization detected by TADpole ﻿

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study ﻿

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC ﻿

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer ﻿

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group ﻿

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer ﻿

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! ﻿

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer ﻿

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review ﻿

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation ﻿

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine ﻿

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations ﻿

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study ﻿

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Hierarchical chromatin organization detected by TADpole

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer

HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial